Leukemia-initiating/repopulating cells (LICs), also named leukemic stem cells, are responsible for propagating human acute leukemia. Although they have been characterized in various leukemias, their role in T-cell acute lymphoblastic leukemia (T-ALL) is unclear. To identify and characterize LICs in T-ALL (T-LIC), we fractionated peripheral blood cell populations from patient samples by flow cytometry into three cell fractions by using two markers: CD34 (a marker of immature cells and LICs) and CD7 (a marker of early T-cell differentiation). We tested these populations in both in vitro culture assays and in vivo for growth and leukemia development in immune-deficient mice. We found LIC activity in CD7 þ cells only as CD34 þ CD7 À cells contained normal human progenitors and hematopoietic stem cells that differentiated into T, B lymphoid and myeloid cells. In contrast, CD34 þ CD7 þ cells were enriched in LICs, when compared with CD34
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Introduction T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of newly diagnosed ALL in children and 25% in adults. T-ALL is generally characterized by a high tumor burden with high peripheral blood blasts counts and extra-medullar localizations that represent high-risk clinical features. Although intensive chemotherapy has markedly improved the prognosis for patients with T-ALL, relapses still occur, often with a dismal outcome. Different analyses have revealed that T-ALL is a highly heterogeneous disease; 1 despite considerable efforts to predict outcome based on biological markers, genetic or immunophenotypic criteria are still limited that correlate clearly with prognosis. T-ALL is thought to result from the transformation of T-cell progenitors blocked either early or late in differentiation. 2 Normal human T-cell differentiation proceeds notably through acquisition or loss of surface markers, such as CD34 and CD7, the former marker being progressively lost as maturation progresses while CD7 expression persists and other markers such as CD1a, CD4, CD8 and CD3 appear. 3 Immature T-ALL often bears CD34 and CD7 surface markers but can lack others such as CD4, CD8 or CD3. The reverse is not always true for cortical or mature T-ALL, as aberrant expression of surface markers such as CD34 can be detected with CD4, CD8 and CD3. 4 The cancer stem cell hypothesis posits that the cells that make up a cancer are functionally heterogeneous and organized in a hierarchy that mimics normal differentiation, with a fraction of cells endowed with self-renewal properties (that is, cancer stem cells) at the apex of the hierarchy. 5 By identifying and characterizing these stem cells in leukemia one hope to learn more about the heterogeneity of cancer cells, how these stem cells initiate and propagate the disease and, in the long-term, to develop specific therapeutic strategies aimed at eradicating the cancer and preventing relapse. 6 Whether T-ALL is organized as a hierarchy of cells, as previously described for acute myeloid leukemia, 7, 8 chronic myeloid leukemia 9 and pediatric B-cell acute lymphoblastic leukemia, 10 ,11 is still unknown. There are few published studies of cell populations enriched in leukemic stem cell activity in human T-ALL, although we and others have previously shown that T-cell leukemia-initiating cell (T-LIC) activity can be explored by using in vivo xenografts and in vitro assays. 12, 13 Indeed, both these studies demonstrated that T-ALL contained a T-LIC activity using serial transplantation experiments into immune-deficient mice that are considered hallmarks for studying cancer stem cells. Moreover, T-LICs were proposed to reside into the population expressing CD34, but not CD7 or CD4, in reference to immature T-cell progenitors. 12 Here, we have investigated the T-LIC activity of distinct cell populations in peripheral blood samples from cortical/ mature T-ALL patients by using a combination of in vitro studies and transplantation into immune-deficient non obese diabetic-severe combined immune deficient (also called NOD-SCID or NS) or NOD-SCIDgc À/À (NSG) mice. We find that these cell fractions are heterogeneous in their functional properties. In contrast to previous reports, 12 CD34 þ CD7 À cells did not contain leukemia-initiating activity but underwent normal hematopoietic differentiation in vitro and in vivo. In fact, leukemia-initiating activity was enriched in CD34 þ CD7 þ cells, compared with CD34 À CD7 þ cells. Moreover, we demonstrate that combination of dexamethasone, a commonly used drug in T-ALL therapy, and inhibitors of NOTCH signaling inhibit proliferation and activity of the stem cell-containing CD34 þ CD7 þ cell population.
Materials and methods

Mice
NOD/Ltsz-scid/scid (NS) and NOD.Cg-Prkdc(scid) Il2rg(tm1Wjll)/ SzJ (NSG) (Jackson Laboratory, Bar Harbor, ME, USA) immunedeficient mice were housed in pathogen-free animal facilities at the CEA, Fontenay-aux-Roses, France. Adult NS and NSG mice were irradiated at 3 Gy and anesthetized with isoflurane before intravenous retro-orbital injection. All experimental procedures were done in compliance with French Ministry of Agriculture regulations (animal facility registration number: A920322) for animal experimentation.
Human samples
All primary samples were obtained with the informed consent of the patients in accordance with national ethics rules. White blood cells were isolated by Ficoll centrifugation, immunophenotyped and used directly or frozen in fetal calf serum containing 10% dimethyl sulfoxide. Normal B, T and myeloid cells were excluded by flow cytometry based on their expression of lymphoid CD19, CD3 (hi) TCRab (hi) CD4 (hi) or CD8 (hi) and myeloid CD14/CD15 markers. In most cases, T-ALL blasts constituted 490% of cells contained in patient peripheral blood samples. Human umbilical cord blood CD34 þ cells were isolated by using immuno-magnetic purification (Myltenyi Biotech, Paris, France).
Culture conditions
Peripheral blood cells from T-ALL patients were cultured as previously described. 13 Briefly, the cells were grown in complete medium containing reconstituted a-MEM supplemented with 10% fetal calf serum (6450; Stem Cell Technologies, Vancouver, Canada) and 10% human serum (J Boy, Reims, France), in the presence of 50 ng/ml recombinant human stem cell factor (Amgen, Neuilly-sur-Seine, France), 20 ng/ml rhFlt3-Ligand (Diaclone, Besançon, France), 20 nM insulin (Sigma-Aldrich, St Quentin Fallavier, France) and 10 ng/ml rhIL-7 (R&D System, Lille, France). g-Secretase inhibitor (GSI) (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; DAPT, Calbiochem, Strasbourg, France) was diluted into dimethyl sulfoxide and added in the culture medium three times a week at the indicated concentration.
Flow cytometry
Cells were stained with fluorescein (FITC-), phycoerythrin (PE-), PE-cyanin 7 (PC7-) and allophycocyanin (APC-) conjugated mouse anti-human monoclonal antibodies specific for CD45, CD34, CD38, CD7, CD4, CD8, CD19, CD14 and CD15 (1:25 dilution; Beckman Coulter, Villepinte, France). Cell-surface marker expression was analyzed on a FacsCalibur cytometer (BD Biosciences, Le Pont de Claix, France). Cell sorting was performed on a Moflow cell sorting cytometer (Triple-laser MLS System, Dako Cytomation, Fort Collins, CO, USA).
In vitro drug sensitivity
Sorted normal and leukemic cells were cultured for a week with MS5-DL1 stromal cells, 13 in the presence of a range of concentrations of dexamethasone (0.1-500 nM; Sigma-Aldrich, D-4902), DAPT (0.5-5 mM) or DAPT (5 mM) þ dexamethsaone (0.1-50 nM), or with the dimethyl sulfoxide/vehicle alone. Cultured cells were harvested and cell cycle commitment was measured by immunolabeling for Ki67 (BD Pharmingen, Grenoble, France) and analyzed by flow cytometry.
Gene expression
Quantitative PCR analysis was performed as previously described with the same primers as in Armstrong et al. 13 Three measurements were performed for each sample and data were normalized over b2m values.
T-cell receptor (TCR) gene rearrangements
Specific clonal rearrangements of TCRg and TCRd genes were detected in leukemic cells at diagnosis according to standard procedures.
14 Briefly, genomic DNA was subjected to several multiplex PCR assays for amplification of recombined V(D)J gene segments. Fluorescently labeled PCR products were analyzed by GeneScanning using an ABI PRISM 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). Clonal rearrangements present in leukemic cells at diagnosis were then searched for in sorted populations and immune-deficient mouse-derived cells by PCR and fragment size analysis.
Notch1 mutations
Sequencing was performed according to Weng et al.
15
TLX3 and SIL-TAL1 genomic rearrangements The TLX3 chromosomal translocation was detected by fluorescence in situ hybridization on interphase nuclei using the TLX3 fluorescence in situ hybridization DNA-specific dual color translocation probe (Dako, Trappes, France). The SIL-TAL1 genomic micro-deletion was detected by genomic PCR of the flanking regions using a fluorescently labeled primer, followed by fragment size analysis.
Statistical analysis
Values are presented as the mean or median ± s.d. Statistical comparisons between groups were done using the Student's t-test, *Po0.05; **Po0.01; ***Po0.001 were considered statistically significant.
Results
Heterogeneous expression of CD34, CD7 and CD4 in T-ALL cells
We first aimed at measuring the proportion of cells positive for surface markers useful for the search of T-LIC. We determined the proportion of CD34-, CD7-and CD4-positive cells in samples of peripheral blood mononuclear cells (MNC) from 18 Table 1) . Interestingly, all samples contained a small proportion of CD34 þ CD7 À cells that were CD4 À ( Figure 1a ). When CD34 was plotted against CD4, we found that most CD34 þ CD4 À cells were CD7 þ , except in some samples where they remained CD7 À ( Figure 1a ). These results indicated that T-ALL is heterogeneous in terms of cell surface CD34, CD7 and CD4 expression.
CD34
þ CD7 À cells undergo normal hematopoiesis
A previous study reported that the leukemic progenitor cell population of T-ALL is contained in CD34 þ CD7 À and CD34 þ CD4 À cells. 12 As we found that T-ALL-derived CD34 þ CD7 À cells are mostly CD4 À (see above), we reasoned that the T-LIC activity would more likely to be found in the CD34 þ CD7 À cell population. Interestingly, the absolute numbers of CD34 þ CD7 À cells were high (3-9 Â 10 8 /l) compared with healthy subjects (2-5 Â 10 7 /l) 16 related to the fact that T-ALL patients have a hyper-leukocytosis. We first co-cultured the sorted CD34
þ CD7 À cells from seven samples in contact with a stromal cell line expressing the human NOTCH ligand DL1 (MS5-DL1), which allows human progenitor cells to differentiate into T cells (La Motte-Mohs et al. 17 and Supplementary Figure 1 ) and human T-ALL to proliferate. 13 In these conditions, T-ALLderived CD34
þ CD7 À cells progressively expressed CD7 while they downregulated CD34 ( Figure 2a ) and CD4 þ CD8 þ T cells were detected 7 weeks later. Interestingly, CD34
þ CD7 À cells generated also myeloid cells in these conditions ( Supplementary  Figures 2A and B) . When the NOTCH pathway was blocked using a GSI called DAPT, the production of CD7 þ T cells, but not CD14 þ /CD15 þ myeloid cells, was severely impaired, indicating that CD7 þ T-cell growth was specifically inhibited and that DAPT was not toxic for myeloid cell develop- Table 2) .
These data suggested that T-ALL-derived CD34 þ CD7 À cells contained normal progenitors. Likewise, we observed that human umbilical cord blood CD34 þ CD38 À/low cells cocultured with MS5-DL1 or MS5-Ctl cells produced similar proportions of differentiated T, B and myeloid cells (Supplementary Figure 1 ). Moreover, the genetic abnormalities characteristic of the tested T-ALL samples they were derived from were not detected in human cells generated during culture. For instance, CD34
þ CD7 À -derived myeloid and T cells from the M60 sample did not express TLX1 transcripts and those from the M77 sample were negative for the TLX3 rearrangement (Supplementary Figure 2C; Figure 2b ). Moreover, only in 1/4 tested samples we could detect at very low level (p1/1000) the clonal TCR rearrangement of leukemic cells in CD7 þ T cells recovered after culture (M79, Supplementary Table 2) , probably explained by a weak contamination of the starting population with leukemic cells. Altogether, these findings indicated that T-ALL-derived CD34 þ CD7 À cells contained normal hematopoietic progenitors capable of multi-lineage differentiation but no leukemic cell development in vitro.
To assess the potential T-LIC activity of these cells, we injected 2.5-5 Â 10 4 sorted CD34 þ CD7 À cells into NS and NSG mice. Mice remained healthy during the entire period of observation. Engraftment analysis showed that 12/16 NS/NSG mice contained detectable (40.1%) levels of human CD45 þ hematopoietic cells, but engraftment did not exceed 5% in bone marrow (BM) and 7% in spleen (Figure 2c ; Supplementary Table 3 ). Phenotypic analysis showed these cells were mainly CD19 þ B cells and CD14 þ /CD15 þ myeloid cells with only a minority of CD7 þ T cells (Figures 2c and 3a) . In all, 4/14 mice also contained human CD7 þ CD4 þ CD8 þ T cells in their thymus (Figure 2c; Supplementary Table 3 ). In comparison, CD34
þ CD7 À cells from T-ALL patients generated myeloid cells as well as B and T cells in NSG mice in similar proportions to those generated by CD34 þ umbilical cord blood cells, although Functional heterogeneity in human T-ALL B Gerby et al at lower levels (Supplementary Table 3 ). The cells recovered from NSG mice transplanted with CD34 þ CD7 À cells from sample M77 did not have the TLX3 rearrangement originally present in the parent sample (Figure 2b) . Analysis of the clonal rearrangements of the TCR genes (TCRg and TCRd) indicated that the CD34 þ CD7 À -derived cells did not exhibit the specific clonal rearrangements present in the sample at diagnosis ( Figure 2d) ; human CD7 þ cells present in the thymus of transplanted mice contained polyclonal TCRg and TCRd gene rearrangements reminiscent of normal T-cell maturation. Furthermore, when these T cells from the thymus were transplanted into secondary recipient mice, they failed to initiate human T-ALL (data not shown). Together, these findings demonstrate that CD34 þ CD7 À cells, isolated from T-ALL patients contain normal hematopoietic stem cells (HSCs) and progenitor cells but no T-ALL leukemic cells.
T-LIC activity is enriched in CD34
þ CD7 þ cells
We know that transplantation of mononucleated cells from T-ALL patients into immune-deficient mice results in leukemia. 13 Furthermore, we found a correlation between the proportion of CD34 þ cells and the LIC activity in several samples we tested (Supplementary Figure 3 ), yet we have demonstrated above that CD34 þ CD7 À cells from most T-ALL patients do not have LIC activity (Figure 3a) . To investigate further the relationship between CD34, CD7 and LIC activity, we sorted CD34 þ CD7 þ and CD34 À CD7 þ cells and transplanted them into NS and NSG mice. We analyzed human CD45 þ CD7 þ leukemic cells in the BM and spleens of the mice as a measure of leukemia development. 13 When doses of 1-5 Â 10 4 CD34 þ CD7 þ cells/mouse were transplanted, 26/29 (89.6%) mice harbored human leukemic cell infiltration (that is, 41% CD45 þ CD7 þ cells) in their BM, whereas when similar numbers (5 Â 10 4 cells/mouse) of CD34 À CD7 þ cells were transplanted, only 11/24 (46%) mice did so (Figure 3a) . Moreover, engraftment levels were higher in mice transplanted with CD34
þ CD7 þ compared with mice transplanted with CD34 À CD7 þ cells (63 versus 1.5% CD45 þ CD7 þ cells, Po0.001; Figure 3a) . We also observed the leukemic cells spread to the spleen: 21/24 (88%) mice transplanted with 
þ -derived cells engrafted into NSG mice are also shown. Representative of two T-ALL.
Functional heterogeneity in human T-ALL B Gerby et al with 6 and 0.6% median engraftment levels. As shown above, 5 Â 10 4 CD34 À CD7 þ cells were significantly less efficient than 2.5-5 Â 10 3 CD34 þ CD7 þ cells (Figure 3a) . In one case (M105, Supplementary Table 1), limiting cell numbers were transplanted and leukemia development was followed up during up to 9 weeks for the lowest cell dose. Limiting dilution and kinetic analysis confirmed the more aggressive behavior and the LIC enrichment of CD34 þ CD7 þ cells as compared with CD34 À CD7 þ cells, although as seen in other samples (Figure 3a) , CD34
þ CD7 À cells also contained LIC activity (Supplementary Figure 5) .
The engrafted human cells exhibited the same genetic abnormality identified at diagnosis (for example, the SIL-TAL1 genomic micro-deletion for M61 and M87 T-ALL) and they had the specific clonal TCR gene rearrangements identified at diagnosis in their respective leukemic cells (Figure 3b and data not shown). Thus, the CD34 þ CD7 þ human cells that engrafted immune-deficient mice derived from the patients' leukemic cells.
To test whether the human leukemic cells recovered from primary mice contained cells with self-renewal properties, we transplanted human leukemic CD45 þ CD7 þ cells recovered from some primary transplanted mice into secondary recipients.
The engraftment efficiency observed in primary mice, namely that cells originating from CD34 þ CD7 þ cells engrafted better compared with CD34 À CD7 þ cells, was reproduced in the secondary mice (Figure 3a) , indicating that CD34 þ CD7 þ cells were endowed with self-renewing capacity.
Together, these results indicate that selection of CD34 þ CD7 þ cells in T-ALL patient samples enriches for T-LIC activity.
Differential responses of CD34 þ CD7 þ and CD34 À CD7 þ cells to NOTCH activation
Signaling through the NOTCH pathway is important in the development/maintenance of T-ALL and is implicated in T-LIC activity. 13 In this section, we assessed the growth capacity of CD34 þ CD7 þ and CD34 À CD7 þ populations purified from eight T-ALL patients (M61, M66, M71, M69, M73, M78, M22 and M105) during co-culture with MS5-Ctl and MS5-DL1. In all tested samples, except one, CD34
þ CD7 þ cells grew faster than did CD34
À CD7 þ cells when co-cultured with MS5-DL1 cells for 4 weeks, although variability in growth curves was observed between individual samples (Figure 4a ; Supplementary Figure  6A) . In accordance, a greater proportion of CD34 þ CD7 þ cells expressed the cell proliferation marker Ki-67 than did Figure 7) . Surprisingly, CD34 þ CD7 þ cells from 7/8 samples also generated leukemic cells upon co-culture with MS5-Ctl cells, although at lower levels than with MS5-DL1 cells, whereas the CD34 À CD7 þ fraction did not (Figure 4a; Supplementary Figure 6A ). Cultured CD34 þ
CD7
þ -and CD34 À CD7 þ -derived human cells had similar patterns of expression of CD4, CD8 and CD34, although CD34 expression was lost during culture with MS5-DL1 stromal support (Figure 4b ). Cultured cells continued to express their oncogenic marker (for instance, TAL1 for M66 T-ALL; Figure 4c ), indicating they were of leukemic origin. High level (10 mM) of GSI and NOTCH signaling inhibitor DAPT completely inhibited the growth of both CD34 þ CD7 þ and CD34 À CD7 þ cells in coculture with either MS5-DL1 or MS5-Ctl stromal cells (Figure 4a ; Supplementary Figure 6A ). These data suggested that NOTCH signaling is implicated in T-LIC cell growth with MS5-DL1 and also with MS5-Ctl cells, which are known to express baseline levels of the NOTCH ligands DL1 and jagged1-2.
18, 19 We further evaluated NOTCH activation in leukemic cells derived from sorted cell fractions after 7-30 days in co-culture by measuring expression of the NOTCH target genes Deltex-1, HES-1 and pTa (Figure 4d; Supplementary Figure 6B) . Expression levels were higher in leukemic cells recovered from MS5-DL1 co-cultures than in those from MS5-Ctl co-cultures, consistent with the growth curves described above. Most importantly, NOTCH target genes were expressed significantly more in CD34
whatever MS5 stromal cells used (Figure 4d ; Supplementary Figure 6B ). Therefore, our data demonstrate that CD34 þ CD7 þ and CD34 À CD7 þ cell populations have differential sensitivity to NOTCH activation in vitro, which correlates with their different growth rates.
Combination of dexamethasone and GSI reduces proliferation and T-LIC activity of CD34
The corticoid-like molecule dexamethasone is commonly used during the induction period of chemotherapy of T-ALL patients. 20 We next investigated whether CD34 þ CD7 þ cells were sensitive to dexamethasone and whether combining dexamethasone with DAPT would interfere with their proliferation compared with dexamethasone alone. Fractionated cells from four T-ALL patient samples (M22, M18, M88 and M105) were co-cultured with MS5-DL1 cells for 7 days in the presence of increasing concentrations of dexamethasone (0.1-500 nM) or DAPT (0.5-5 mM) or a combination of the two, dexamethasone (0.1-50 nM) þ DAPT (5 mM). For two samples (M22 and M88), the cell fraction CD34
À CD7 þ was also tested. We observed a consistent dose-dependent sensitivity of CD34 þ CD7 þ cell fraction to treatment with either dexamethasone or DAPT, whereas CD34
À CD7 þ cells behaved more variably as a result of their low activation status when cultured with MS5-DL1 stromal cells (Figure 5a; Supplementary Figure 8A) . Interestingly, treatment with a combination of DAPT and 5-50 nM dexamethasone additively inhibited cell growth of both cell fractions. 
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Finally, in order to test the efficiency of DAPT þ dexamethasone treatment on T-LIC activity, we transplanted residual cells recovered from cultures of CD34 þ CD7 þ cells from two T-ALL (M18 and M105), treated or not with dexamethasone and DAPT, into NSG mice (Figure 5b and c; Supplementary Figure  8B ). M105 T-ALL cells were injected at limiting dilution. We found that although T-LIC activity was still detected in drugtreated cells, the levels of leukemic cells in the BM and spleens of mice transplanted with the drug-treated CD34 þ CD7 þ cells were decreased compared with control, vehicle-treated cells (Figure 5c ). Furthermore, the limiting dilution experiment combined with the kinetic analysis of drug-treated cells compared with controls indicates that treatment reduced the T-LIC frequency in the CD34 þ CD7 þ cell compartment (Figures  5c and d; Supplementary Figure 8) . As only few cells (410-fold less) were recovered in culture after 7 days treatment with dexamethasone þ DAPT compared with vehicle-treated control cells (Figure 5b; Supplementary Figure 8B ), these data show that combined dexamethasone þ DAPT treatment dramatically reduces the overall T-LIC activity of CD34 þ CD7 þ cells.
Discussion
Current chemotherapeutic agents were originally developed to act against the bulk of malignant cells rather than any putative cancer-initiating/repopulating cells. Consequently, LICs may resist current chemotherapies and may contribute to relapse of the disease. 6 Several studies indicate a central role of initiating cells in the pathogenesis of leukemias, implying that targeting these cells specifically could help to eradicate the disease and prevent relapses. Toward this goal, our work is aimed at investigating heterogeneity of cell populations in human T-ALL and at providing new insights to help the cure of such blood disorders.
We first demonstrate here that CD34 þ CD7 À cells in the blood of T-ALL patients neither generate blast cells in vitro nor promote leukemia in immune-deficient mice. In fact, in all, but one, samples tested, these cells give rise to human B, T and myeloid hematopoietic cells that are not of leukemic origin, indicating the presence of normal HSC and progenitor cells in this population. This is similar to what has been described for CD34 þ CD19 À CD10 À CD38 À cells in B-ALL patients 10, 21 and is consistent with the clinical observation that patients treated with high-dose chemotherapy eventually restore normal hematopoiesis, implying that residual normal progenitors/HSC are present. In agreement with a previous study, 22 hematopoietic reconstitution from CD34 þ CD7 À cells was quiet inefficient compared with CD34 þ cells isolated from umbilical cord blood, reflecting the presence of high progenitor/HSC ratio in patient blood or an ontogeny difference between both cell sources. 23 Interestingly, the absolute numbers of CD34 þ CD7 À normal cells in peripheral blood of T-ALL patients are high compared with healthy subjects, suggesting either an abnormal proliferation or a mobilization of the normal HSC/progenitors in patient blood possibly related to high leukemic cell infiltration of the BM.
Our observation that CD34 þ CD7 À T-ALL cells do not have LIC activity appears to contradict an earlier study by Cox et al. 12 that reported that CD34 þ CD4 À and CD34 þ CD7 À cells were capable of NOD/SCID engraftment. This might be explained by the fact that the cell populations in the two studies were different. In our study here, the CD34 þ cells were both CD7 þ CD7 þ CD4 À , like the cells that we found had LIC activity. Another possibility would be that either study did not work with similar T-ALL cohorts: we mostly studied mature/ cortical T-ALL and probably immature T-ALL would have greater LIC activity in more primitive-like populations.
In fact, in our experiments T-LIC activity is present only in CD7 þ cells, implying that leukemia development or maintenance relies on a cell population already engaged in T-cell differentiation. 3 This conclusion is consistent with the recently published work on Lmo2-induced T-cell leukemia in mouse, that takes its first steps in the thymus, 24 and with the fact that most genomic rearrangements in T-ALL that are thought to be primary oncogenic events occurred during TCR V(D)J region recombination and thus probably occur in differentiating T-cell precursors. 1 Moreover, we found that T-LICs were particularly enriched in CD34 þ CD7 þ cells compared with CD34 À CD7 þ cells. The enrichment of LICs in the CD34 þ CD7 þ cell fraction might correlate with a high aggressiveness in patients, as it has been recently reported a correlation between the expression of CD34 and the prognosis of T-ALL. 4 Our results indicate that LIC activity is also detected, although to lower levels, in the CD34 À CD7 þ cell population. This implies that in T-ALL samples in which this population is major, the LICs are at least as numerous in CD34
À CD7 þ populations as in CD34 þ CD7 þ populations. These findings are consistent with a very recent paper on acute myeloid leukemia that reported that, in certain samples, LIC activity was found in CD34 À cell populations. 25 This suggests that additional markers, such as the CD90 (Thy1) marker 26 or Hoechst dye exclusion, will be necessary to further purify LICs from T-ALL samples.
Transplantation into immune-deficient mice may select for cells that have an advantage to grow in a xenogenic environment and/or that escape from residual mouse immune activity, as previously reported for normal and acute myeloid leukemia cells where CD47 expression help escaping from the mouse macrophages. 27, 28 CD34 is traditionally seen as an immature cell marker. 16 On the other hand, CD34 belongs to a sialomucin protein family with anti-adhesive properties, implicated in cell trafficking and migration of hematopoietic progenitor cells to the BM. 29, 30 CD34 expression on CD7 þ T-ALL cells is mostly not related to an immature stage of differentiation but rather to an aberrant expression as T-ALL samples we studied belong to the mature/cortical T-ALL immunologic subtypes, and thus differ from the early T-cell precursor leukemia subtype recently characterized. 31 Thus, expression of CD34 might confer migration or adhesiveness properties to leukemic cells that may contribute to the LIC activity of CD34 þ CD7 þ cells. We previously demonstrated that signaling through NOTCH is crucial for the maintenance/amplification of LICs from T-ALL patients. 13 We extend this finding here by showing that the CD34 þ CD7 þ population is more sensitive to NOTCH activation than CD34 À CD7 þ T-ALL cells. Consistent with this, CD34 þ CD7 þ cell proliferation was easily inhibited by the NOTCH signaling inhibitor DAPT, but also by the corticoid-like molecule dexamethasone, these drugs having additive effects on the proliferation of this particular T-ALL cell fraction, as previously reported for T-ALL cell lines and a few patient samples. 32 This finding is surprising because one might expect the LICs to be quiescent and thus more resistant to drugs than the non-T-LIC cell fraction. 33 This has been recently addressed in another study on T-ALL. 34 However, as T-LIC phenotype, T-ALL samples and the experimental design differ between our study and the Chiu's study, comparison of results may be difficult. One explanation may reside in the assay we used, that is, NOTCH activation during co-culture with MS5-DL1 cells. However, as coculture of leukemic fractions with stromal cells may reflect the in vivo niche context, combining dexamethasone and GSI treatment of CD34 þ CD7 þ enriched T-LIC very efficiently decreased T-LIC activity, indicating that such treatment could be interesting for patients. It is, however, necessary to acknowledge the fact that inhibiting NOTCH pathway as a therapeutic strategy might be limited to samples where PTEN and/or FBW7 are not mutated or lost as it would interfere with GSI sensitivity. 35, 36 In fact, it would be of great interest to test such primary samples in vitro and in vivo with combination of drugs as most previous studies have been done with cell lines that probably do not faithfully reflect the behavior of patient samples.
Conclusions
Altogether, the findings reported in this paper show that cells in human T-ALL samples are heterogeneous in terms of their CD34, CD7 and CD4 marker expression and in terms of normal hematopoiesis and initiation/repopulation of leukemia in immune-deficient mice. We find the LIC activity enriched in CD34
þ CD7 þ cells, but not in CD34 þ CD7 À cells that give rise to normal hematopoiesis. We further show that NOTCH activation is crucial for LIC activity from CD34 þ CD7 þ cells and inhibition of such pathway can efficiently interfere, in combination with corticoid-like molecule, with leukemia development in xenograft models. These findings provide a base for studying and understanding LICs in T-ALL, and new avenues for the development of promising therapeutics.
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